Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Primary Handling Editors: Keith Syson Chan, Christina Karlsson Rosenthal and Mengtan Xing
doi: 10.3389/fendo.2018.00725 Received 17 August 2018 Accepted 15 November 2018 Published 29 November 2018 Volume 9 - 2018 Edited by Richard Ivell, University of Nottingham, United Kingdom Reviewed by Giuliano Marchetti Bedoschi, Universidade de So Paulo, Brazil
Its unclear if the price changes based on the dosage
In the 1990s, exendin-4, a GLP-1 receptor agonist (GLP-1 RA) structurally similar to endogenous GLP-1, was isolated from Gila monster venom, which subsequently led to the approval of exenatide for type 2 diabetes mellitus (T2DM) management in 2005 [2]
Supplementary searches were performed to identify overview of approved AOMs and background information
None of these four frameworks excludes the others, and none has been established as the operative mechanism
US$ 27.03
US$ 26.39
US$ 25.39
US$ 26.88
US$ 22.43
US$ 24.69
